Not real patients
The length of attacks, days of swelling and severity of attacks were also measured. When adult and adolescent patients treated with CINRYZE experienced HAE attacks, they were shorter and less severe.
The safety and effectiveness of CINRYZE were evaluated in a 24-week clinical trial of 22 adults and adolescents. Participants in the study were diagnosed with HAE and had a history of at least two attacks per month. Patients were divided into two groups: one group received CINRYZE for the first 12 weeks and switched to placebo for the last 12 weeks; the other group received placebo for the first 12 weeks and switched to CINRYZE for the last 12 weeks.
Talk to your doctor to see if preventative therapy with CINRYZE might be right for you or a loved one.
Create your discussion guide